Press releases

Cancel
  • Bacteriophages join the fight against infection / 2017

    Research alliance launched, aimed at establishing bacteriophages as an approved drug

    9.11.2017

    (Hannover, Germany) Bacteria worldwide keep developing new resistances to antibiotics. Alternative therapies are urgently needed to meet this challenge. To this end, the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Charité – Universitätsmedizin Berlin, and Charité Research Organisation have teamed up and initiated the project “Phage4Cure”. The goal is to establish bacteriophages as an approved drug for treating bacterial infections. The German Federal Ministry of Education and Research is funding this project with almost four million euros over a period of three years.

    more info
  • The Hannover Science Initiative is celebrating its anniversary: for 10 years now, the 15 partners in the Initiative, among them Hannover’s nine universities and higher-education institutes, the Student Administration, science-affiliated institutions such as the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, hannoverimpuls GmbH, and the State Capital of Hannover, have been successfully cooperating.

    more info
  • Researchers from the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM have teamed up with colleagues from the Hannover Medical School (MHH) and Griffith University’s Institute for Glycomics (IfG) in Gold Coast, Australia, in the iCAIR (Fraunhofer International Consortium for Anti-Infective Research) project. They have set themselves the ambitious goal of closing the gap from the discovery of new agents to their development by the pharmaceutical industry into potential medications and developing new anti-infective drugs.

    more info
  • (Hannover/Germany) The 40 million euro European project eTRANSAFE, kicked off at the end of September 2017, is aimed at speeding up the development of better and safer medicines for patients. Coordinated by the Fundació Institut Mar d'Investigacions Mèdiques (IMIM) and led by the pharmaceutical company Novartis, the project consortium is a public-private partnership of eight academic institutions, six SMEs, and twelve pharmaceutical companies. One of the project partners is Fraunhofer ITEM.

    more info
  • Cooperation in Hannover to promote fast transfer of research results into clinical trials / 2017

    New High-Performance Center Translational Medical Engineering

    25.4.2017

    (Hannover) Together with representatives from industry, government and academia, Dr. Gabriele Heinen-Kljajić, Minister for Science and Culture of Lower Saxony, and Prof. Reimund Neugebauer, President of the Fraunhofer-Gesellschaft inaugurated the High-Performance Center Translational Biomedical Engineering in Hannover on April 25.

    more info
  • (Hannover, Germany) After 21 years of successful leadership, Professor Uwe Heinrich ceded his position as Fraunhofer ITEM executive director to Professor Norbert Krug as of January 1, 2017.

    more info
  • (Hannover/Regensburg, Germany) Scientists of the Regensburg-based Project Group for Personalized Tumor Therapy (Fraunhofer ITEM/University of Regensburg) and colleagues from Icahn School of Medicine at Mount Sinai discovered new mechanisms of early metastatic spread in breast cancer. Results have been published in the latest issue of the renowned journal Nature (doi:10.1038/nature20785, doi:10.1038/nature20609).

    more info
  • The new EU-wide Medical Device Regulation (MDR) is scheduled to become effective in mid-2017, entailing consequences for manufacturers of medical devices. Among other obligations, they will be required to provide more documentation to comply with the new legislation. The expertise pooled at Fraunhofer ITEM, in particular in the Division of Translational Biomedical Engineering, enables comprehensive support in the implementation of the new regulation.

    more info
  • (Hannover, Germany) The Fraunhofer-Gesellschaft, on behalf of the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, has signed an asset transfer agreement with Takeda GmbH to exclusively transfer its Surfactant and Continuous Powder Aerosolization (CPA) program assets to Fraunhofer ITEM. The transfer includes the CPA technology platform – the technology for continuous aerosolization of powdery substances – and the know-how to manufacture recombinant surfactant protein C, together with the associated intellectual property. The Fraunhofer ITEM is thus in a position to continue the development of therapies involving continuous inhalation of surfactant and other medications, begun 10 years ago as contract research on behalf of industry.

    more info